As NASH Space Heats Up, Tobira Strengthens Position With Regado Reverse-Merger
This article was originally published in The Pink Sheet Daily
New combined company, with $60 million in cash, is hoping to move quickly to fill the unmet medical need of non-alcoholic steatohepatitis. Tobira expects primary endpoint data from a Phase IIb study of cenicriviroc by the second quarter of 2016.
You may also be interested in...
Amgen moves into the chimeric antigen receptor T-cell space in cancer under a complex partnership with Kite Pharma. Gilead, Isis and Janssen agree to multiple deals during and after the holiday season, while scuttled deals return assets or rights to Vanda, AMAG and OncoGenex.
Fresenius Kabi insists there is a “business plan behind everything” as it divulged a higher cost savings goal for the end of next year, following a fruitful 2023. But queries over margins led the company to stress that it was combatting a variety of uncertainties, especially in China and for its burgeoning biosimilars unit.
The new committee, which will initially be in place for a year, will advise the French drug regulator when it is preparing its opinions on substitution in specific biosimilar product groups.